<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Left ventricular assist device (LVAD) infections</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Left ventricular assist device (LVAD) infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Left ventricular assist device (LVAD) infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Zerelda Esquer Garrigos, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Margaret M Hannan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anelechi Anyanwu, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Rizwan Sohail, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donna Mancini, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1961062427"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A durable left ventricular assist device (LVAD) can be used to treat advanced heart failure as a bridge to heart transplantation in eligible patients or as destination therapy for patients who are not eligible for transplant [<a href="#rid1">1,2</a>]. Infection is an important cause of morbidity and mortality in patients supported with an LVAD [<a href="#rid3">3,4</a>]. </p><p>This topic will discuss the epidemiology, clinical manifestations, diagnosis, management, and prevention of LVAD infections. </p><p>Indications for LVAD placement and other associated complications are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3459.html" rel="external">"Treatment of advanced heart failure with a durable mechanical circulatory support device"</a>.)</p><p class="headingAnchor" id="H113178750"><span class="h1">HARDWARE COMPONENTS</span><span class="headingEndMark"> — </span>An LVAD consists of a continuous-flow pump within a metal housing that is typically anastomosed to the apex of the heart  (<a class="graphic graphic_figure graphicRef138618" href="/d/graphic/138618.html" rel="external">figure 1</a>). The pump housing is connected to an external power source via a driveline cable that tunnels through the abdominal wall before exiting the skin in the left or right subcostal region. The driveline has a roughened velour material to facilitate adhesion to the subcutaneous tissues along the course of the tract. </p><p class="headingAnchor" id="H1804648342"><span class="h1">TYPES OF LVAD INFECTION</span><span class="headingEndMark"> — </span>The types of LVAD infection include driveline infection, extravascular pump infection, and endovascular pump infection; one or more types of infection may coexist simultaneously:<strong> </strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driveline infection</strong> – An infection of the driveline and/or its surrounding tissues  (<a class="graphic graphic_picture graphicRef141203" href="/d/graphic/141203.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef141205" href="/d/graphic/141205.html" rel="external">picture 2</a>). (See <a class="local">'Driveline infection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extravascular pump infection</strong> – An infection of the extravascular components of the LVAD  (<a class="graphic graphic_picture graphicRef141204" href="/d/graphic/141204.html" rel="external">picture 3</a>). (See <a class="local">'Extravascular pump infection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endovascular pump infection</strong> – An infection of any surface of the device that interfaces with the bloodstream. This can include the inflow cannula, blood contacting surfaces of the pump, and the outflow graft. (See <a class="local">'Endovascular pump infection'</a> below.)</p><p></p><p>The International Society for Heart and Lung Transplant (ISHLT) Infectious Disease Working Group published standardized diagnostic criteria and definitions of LVAD infections in 2011 [<a href="#rid3">3</a>]. The ISHLT definitions are as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>VAD-specific infections</strong> – Ventricular assist device (VAD)-specific infections include infections that are related to the device hardware; these include driveline infection, extravascular pump infection, and endovascular pump infection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VAD-related infections</strong> – VAD-related infections refer to infections that can also occur in patients who do not have VADs; however, there may be unique considerations in patients with VADs with respect to making the correct diagnosis or determining the cause-and-effect relationship (examples include mediastinitis and infective endocarditis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-VAD infections</strong> – Non-VAD infections are unlikely related to the VAD but are included to encourage comprehensive and comparable data recording of all infections among VAD recipients.</p><p></p><p class="headingAnchor" id="H3471305455"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1934547330"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The incidence of LVAD infection is illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study including 10,171 patients with mechanical circulatory support devices and 6758 infection episodes (classified based on the International Society for Heart and Lung Transplant definitions), rates of LVAD infection (eg, driveline infection) and LVAD-related infections (eg, mediastinitis) over a three-year period were 25.9 and 7.4 percent, respectively [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study including 14,607 LVAD recipients, the risk of infection was comparable in the early (within 90 days) and later periods (&gt;90 days) following LVAD implantation (0.16 versus 0.175 events per patient year, respectively) [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review including 132 studies of LVAD recipients, the frequency of infection (by type) at one-year postimplant was [<a href="#rid7">7</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Driveline infection − 7 to 71 percent </p><p class="bulletIndent2"><span class="glyph">•</span>Extravascular pump infection − 0.4 to 10 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Endovascular pump infection − 2.2 to 13 percent </p><p></p><p class="headingAnchor" id="H3390978191"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>The patient and device factors that increase the risk of infection include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age </strong>– Age &lt;50 years may be associated with increased risk of driveline infection, due to higher level of physical activity and consequent mechanical trauma at the exit site [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbidities</strong> – Comorbidities such as diabetes and obesity may increase the risk of LVAD infection [<a href="#rid9">9-11</a>]. In a meta-analysis including 15 studies and more than 17,000 patients with LVAD implants, obesity was associated with increased risk of device-related infection (risk ratio 1.48, 95% CI 1.25-1.75) [<a href="#rid12">12</a>]. Another analysis including 341 patients who underwent LVAD implantation found that those with diabetes had a higher risk of device infection (hazard ratio [HR] 2.1, 95% CI 1.4-3.1) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial factors </strong>– A number of psychosocial factors may be associated the risk of LVAD infection. In an analysis including more than 15,000 patients who received a continuous-flow LVAD, presence of one or more psychosocial risk factors (eg, limited social support, limited cognition, substance use disorder, severe psychiatric disease; HR 1.23, 95% CI 1.10-1.37) and repeated noncompliance (HR 1.49, 95% CI 1.27-1.76) were associated with a higher risk of device infection [<a href="#rid13">13</a>]. Presence of two or more psychosocial risk factors was associated with a higher risk of driveline infection compared with patients with one risk factor (adjusted HR 1.22, 95% CI 0.80-0.91).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior cardiac procedures </strong>– Prior cardiac surgery and temporary mechanical circulatory support may increase the risk of LVAD infection [<a href="#rid11">11</a>]. In a post hoc analysis of a randomized trial that included 515 patients implanted with a HeartMate 3 and 505 patients with a HeartMate II, preimplant use of an intra-aortic balloon pump and history of cardiac surgery were independently associated with an increased risk of infection (HR 1.33, 95% CI 1.12-1.69 and HR 1.28, 95% CI 1.06-1.55, respectively) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">However, in a subsequent analysis that included 112 patients with a continuous-flow LVAD, the rates of sternal wound infection and overall infection were not statistically different between patients who had a prior sternotomy and those without prior sternotomy (8.3 versus 3.8 percent, and 8.3 versus 24.5 percent, respectively) [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driveline placement</strong> – At implantation, the velour portion of the driveline can be placed internally, such that it does not protrude into the driveline exit site. This approach to driveline placement (“silicone interface”) may reduce the risk of driveline infection by 50 percent in the first year [<a href="#rid15">15,16</a>]. </p><p></p><p class="headingAnchor" id="H2788457150"><span class="h1">PATHOGENIC MECHANISMS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driveline infection</strong> – Drivelines are designed with a roughened velour material to facilitate adherence to host tissues, which is intended to create a seal against the environment, but given the course of the driveline between the environment and the body, the potential for driveline infections exists. Mechanisms of driveline infection include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incomplete incorporation of the driveline</strong> – Adherence between the driveline and the skin tract does not always occur. In patients who have incomplete incorporation of the driveline, organisms may more easily ascend via the driveline. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Driveline trauma or movement</strong> – In addition, trauma to the driveline from shearing traction or torsion injury can disrupt driveline integration into the tissue, which increases the risk for infection. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biofilm formation</strong> – Whenever organisms colonize the driveline, biofilm can develop that allows organisms to remain dormant for months or years before clinical manifestations of infection develop. Biofilm formation creates a sanctuary from host defense mechanisms and antibiotics, making cure very challenging [<a href="#rid17">17,18</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pump infection (extravascular or endovascular)</strong> – Pump infection may be caused by hematogenous seeding due to bacteremia originating from another primary site or by contamination during initial placement [<a href="#rid17">17,19</a>].  </p><p></p><p class="headingAnchor" id="H1130447641"><span class="h1">MICROBIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacteria</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gram-positive organisms</strong> – Gram-positive organisms are the leading cause of LVAD infections, responsible for half of all reported cases. <em>Staphylococcus aureus</em> is the predominant pathogen, followed by coagulase-negative staphylococci (CoNS) [<a href="#rid20">20,21</a>]. Gram-positive infections that occur ≤90 days after LVAD implantation are likely acquired from contamination with skin flora at the time of implantation [<a href="#rid22">22,23</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gram-negative organisms</strong> – Gram-negative pathogens are the second most common group of organisms associated with LVAD infection, responsible for 41 percent of cases. Among these, <em>Pseudomonas aeruginosa</em> is the most prevalent, followed by Enterobacterales [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent2">Infections due to gram-negatives typically occur &gt;90 days following LVAD implantation [<a href="#rid23">23</a>]. Acquisition of gram-negative pathogens in these patients is thought to occur after frequent contact with health care or humid environments [<a href="#rid21">21,24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multidrug-resistant organisms</strong> – LVAD infections involving multidrug-resistant organisms have been described [<a href="#rid25">25</a>]. Risk factors include prolonged duration of LVAD support, obesity, and exposed velour portion of the driveline through the exit site. The most common organisms with multidrug resistance include <em>S. aureus, P. aeruginosa</em>, CoNS, <em>Escherichia coli,</em> and <em>Klebsiella</em> spp. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fungi</strong> – LVAD infections due to fungal organisms are relatively rare (&lt;7 percent) [<a href="#rid26">26</a>]. LVAD infections due to <em>Aspergillus</em> and <em>Mucor</em> spp are exceedingly rare [<a href="#rid27">27-29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nontuberculous mycobacteria</strong> – LVAD infections due to nontuberculous mycobacteria have been reported sporadically; one series included eight cases [<a href="#rid30">30</a>]. Causative organisms in this report included <em>Mycobacterium abscessus</em> (n = 2), <em>Mycobacterium fortuitum</em> (n = 2), <em>Mycobacterium chimaera</em> (n =2), <em>Mycobacterium chelonae</em> (n = 1), and <em>Mycobacterium intracellulare </em>(n = 1). There were six driveline infections. The timing of presentation ranged from 5 to 60 months. </p><p></p><p class="headingAnchor" id="H4182060396"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General symptoms and signs</strong> – Most patients with LVAD infection present with erythema and/or purulent discharge at the driveline exit site, pain along the driveline tract, or pain involving the left chest wall (the typical LVAD pump site)  (<a class="graphic graphic_picture graphicRef141203" href="/d/graphic/141203.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef141205" href="/d/graphic/141205.html" rel="external">picture 2</a>). Patients may also present with fever or other systemic symptoms (eg, anorexia, fatigue) [<a href="#rid20">20,21,31</a>].</p><p></p><p class="bulletIndent1">Vascular (eg, septic emboli and cerebrovascular accidents) and immunologic phenomena (eg, glomerulonephritis) may develop [<a href="#rid32">32</a>]. These are described separately. (See  <a class="medical medical_review" href="/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac and/or device abnormalities</strong> – Patients with LVAD infection may present with heart failure exacerbation or other cardiac abnormalities (eg, arrhythmias).</p><p></p><p class="bulletIndent1">It is rare for LVAD infection to cause abnormal device function. However, patients with dehydration, systemic inflammatory response syndrome, or other sequelae of infection may have low pulsatility index or low-flow alarms. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory abnormalities</strong> – Patients with an LVAD infection may have a rising white blood cell count or evidence of deterioration of end-organ function (eg, acute kidney injury).</p><p></p><p class="headingAnchor" id="H3565664954"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The initial assessment consists of the following components: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>History and physical examination</strong> – The history should review any changes to the driveline exit site or changes in wound care regimen prior to presentation, history of driveline or device trauma, and signs or symptoms that may localize an infection to a site other than the device (eg, urinary symptoms, respiratory symptoms). </p><p></p><p class="bulletIndent1">The physical examination should be focused on assessment of the driveline exit site and the skin and deep tissues along the course of the driveline tunnel. We inspect and palpate the area for signs of inflammation, exudate, tenderness, swelling, or fluctuation. There may also be discharging sinuses, distinct from the driveline exit site, related to the course of the driveline. A sinus tract from the pump to the skin may occasionally develop in the lateral chest wall; this is more typically encountered in patients where the device had been implanted through a left thoracotomy [<a href="#rid3">3,21</a>].  </p><p></p><p class="bulletIndent1">In addition, patients should be evaluated for symptoms and signs of infective endocarditis. (See  <a class="medical medical_review" href="/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis", section on 'Symptoms and signs'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – The initial evaluation includes: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blood cultures</strong> – At least two sets of blood cultures should be obtained from separate anatomic sites. Ideally, blood cultures should be obtained from peripheral veins via separate venipuncture sites. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drainage cultures</strong> – If purulent drainage is present at the driveline exit site, drainage material should be sent for bacterial, mycobacterial, and fungal stain and culture. If radiographic imaging demonstrates abscess, image-guided aspiration or surgical drainage should be pursued and material should be sent for culture. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory tests</strong> – A complete blood count and complete metabolic panel should be obtained. Inflammatory markers such as erythrocyte sedimentation rate, C-reactive protein, and procalcitonin can be obtained, but there are no data to support their use. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional studies</strong> – Additional studies to rule out alternative causes of infection should be guided by symptoms; these may include urinalysis, chest radiograph, and sputum Gram stain and culture.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further evaluation</strong> – Further evaluation should be guided by the clinical assessment: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected driveline and/or extravascular pump infection</strong> – For patients with inflammation at the driveline and/or pocket sites, we typically obtain computed tomography (CT) of the chest and abdomen to define the extent of infection, evaluate for drainable fluid collection or abscess, and assess for complications that may require surgical intervention [<a href="#rid33">33</a>]. </p><p></p><p class="bulletIndent2">Typical radiographic signs of a driveline infection consist of stranding and induration around the driveline. Rim-enhancing fluid collections around the pump, outflow graft, or driveline are suggestive of extravascular pump infection, mediastinal infection, or driveline abscess, respectively.</p><p></p><p>If an operation is performed to treat a driveline or extravascular pump infection, tissue and any extracted hardware should be submitted for bacterial, mycobacterial, and fungal stain and culture, as well as histopathology.</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected endovascular pump infection</strong> – For patients with systemic symptoms such as hemodynamic instability, bacteremia, device malfunction, and/or vascular or immunologic phenomena, additional tools for further evaluation include echocardiography and radiographic imaging:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Echocardiography</strong> – Transthoracic echocardiography (TTE) should be pursued to evaluate for echodensity, intracardiac mass, or abscess. If the initial TTE is unrevealing, a transesophageal echocardiogram (TEE) may be useful to evaluate for masses around the inflow cannula (which could represent vegetations) and to exclude heart valve or pacemaker lead endocarditis (as alternative sources of bacteremia). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Radiographic imaging</strong> – The sensitivity of CT for diagnosis of infection involving the inner surface of the device is low; in one study that included 66 patients with endovascular LVAD infection, CT was normal in 55 percent of cases [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent3">If available, fluorodeoxyglucose positron emission (FDG PET)/CT may be useful for evaluation of patients with suspected LVAD-specific infection in whom CT or echocardiography are nondiagnostic. In a pooled analysis of 10 studies including 256 FDG PET/CT scans, the sensitivity and specificity for diagnosis of LVAD infection were 95 and 91 percent, respectively [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent3">However, reactive uptake around the LVAD can persist for months or years after LVAD implantation, leading to false-positive findings [<a href="#rid35">35</a>]; for this reason, the FDG PET/CT should be used only when there is a high pretest probability for infection (as opposed to a ‘screening test’ for an LVAD infection).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tissue and device cultures</strong> – For patients who undergo surgery for management of infection, intraoperative cultures should include samples from tissue around the pump and cannulas, aspirates from the inflow and outflow cannulas, and culture of <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> instilled into the pump. These samples should be submitted for bacterial, mycobacterial, and fungal stain and culture, as well as histopathology.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with negative cultures</strong> – For patients with negative cultures (including blood and operative cultures) in the setting of high clinical suspicion for LVAD infection, molecular diagnostic testing (such as 16S ribosomal ribonucleic acid [rRNA] polymerase chain reaction/sequencing) is warranted. While thus far the utility of this approach has not been well described for LVAD infection, it has been used in the setting of culture-negative endocarditis. </p><p></p><p class="headingAnchor" id="H2574388579"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H468712979"><span class="h2">Driveline infection</span><span class="headingEndMark"> — </span>A definitive diagnosis of driveline infection is based on culture results from drainage material obtained from the driveline exit site. A presumptive clinical diagnosis may be made in the setting of signs of infection at the driveline site that are not otherwise explained (such as traumatic injury or hypersensitivity reaction). </p><p>Driveline infections may be classified further as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncomplicated infection</strong> – Uncomplicated driveline infection refers to the presence of inflammation (erythema, edema, and warmth) and drainage at the driveline exit site or surrounding tissues, in the absence of abscess, necrosis, or systemic inflammatory response syndrome criteria [<a href="#rid3">3,21,36</a>]. (See  <a class="medical medical_review" href="/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complicated infection</strong> – Complicated driveline infection refers to the presence of inflammation and drainage, in addition to systemic inflammatory response syndrome criteria or abscess, necrosis, or sepsis [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H1107156520"><span class="h2">Extravascular pump infection</span><span class="headingEndMark"> — </span>A definitive diagnosis of extravascular pump infection is based on positive operative cultures or histopathologic findings.</p><p>For patients who do not undergo operative intervention, a presumptive clinical diagnosis may be made in the setting of radiographic imaging demonstrating findings consistent with an infection (including fluid collection, enhancement, gas, or sinus tract) and positive culture of image-guided aspiration material [<a href="#rid3">3</a>]. Aspirate cultures must be interpreted carefully. As an example, growth of common skin colonizers (such as coagulase-negative staphylococci or <em>Cutibacterium</em> spp) in small quantities may not necessarily reflect infection; such data should be reviewed in the context of other clinical and radiographic findings. </p><p class="headingAnchor" id="H2557811596"><span class="h2">Endovascular pump infection</span><span class="headingEndMark"> — </span>The diagnosis of endovascular pump infection may be established clinically by positive blood cultures as well as echocardiographic and/or radiographic findings (including echodensity, intracardiac mass, mass around the inflow cannula, or abscess). If the device is removed, additional diagnostic criteria include positive operative cultures and histopathologic criteria [<a href="#rid3">3</a>]. </p><p>Evaluation for alternative causes of bacteremia (including heart valve endocarditis, pacemaker lead endocarditis, or catheter infection) is also warranted. (See  <a class="medical medical_review" href="/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a> and  <a class="medical medical_review" href="/d/html/2138.html" rel="external">"Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2146.html" rel="external">"Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3813.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H1027522900"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3776728830"><span class="h2">Driveline infection</span><span class="headingEndMark"> — </span>Outpatient management is appropriate for patients with uncomplicated driveline infection (with oral antibiotic therapy, if susceptibility data permits), while patients with a complicated driveline infection require inpatient management. In general, the management of driveline infections consists of collecting blood and drainage cultures, followed by initiation of antibiotic therapy; surgical debridement or image guided drainage is warranted in some circumstances [<a href="#rid4">4</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncomplicated driveline infection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empiric antibiotic therapy</strong> – For patients who are clinically stable but have substantial erythema, drainage, or skin warmth , we initiate empiric oral antibiotic therapy with a regimen active against methicillin-resistant <em>S. aureus </em>(MRSA; such as <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>) and <em>Pseudomonas</em> spp (such as <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>). </p><p></p><p class="bulletIndent2">Uncomplicated driveline infections can usually be managed in the outpatient setting. However, in the setting of rapid progression of erythema or drainage, positive blood cultures, or lack of clinical improvement within 48 hours of starting oral antibiotic therapy, we pursue inpatient admission for parenteral therapy (outlined below). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tailoring antibiotic therapy</strong> – Antibiotic therapy should be tailored to culture results and susceptibility data when available. If cultures are negative but clinical improvement is observed on the empiric regimen, this regimen (or an alternative regimen with comparable spectrum of activity) may be continued.</p><p></p><p class="bulletIndent2">For patients with uncomplicated driveline infection confined to the incision site and subcutaneous tissue, we treat with oral antibiotic therapy for at least two to four weeks, after which the duration should be guided by clinical improvement [<a href="#rid4">4</a>]. Prior to discontinuation of antibiotic therapy, patients should be evaluated to ensure complete resolution of symptoms. Patients with persistent symptoms should be managed as complicated infection (outlined below). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complicated driveline infection with negative blood cultures</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotic therapy</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Empiric antibiotic therapy</strong> − For patients who present with hemodynamic instability and/or progressive inflammation at the driveline site, we initiate empiric parenteral antibiotic therapy with a regimen active against MRSA (such as <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>) and <em>Pseudomonas</em> spp (such as <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> or <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>); for patients with hemodynamic instability in the setting of underlying immunosuppression, some also include empiric antifungal treatment with an echinocandin. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Tailoring antibiotic therapy</strong> − Antibiotic therapy should be tailored to culture and susceptibility data when available. Parenteral therapy is preferred in cases of complicated driveline infection; if drainage culture susceptibility data permit, highly bioavailable oral agents may be considered. </p><p></p><p class="bulletIndent3">We treat patients with deep or complicated driveline infection until clinical stabilization and improvement of infection (usually six to eight weeks) with close follow-up [<a href="#rid4">4,37</a>]. Prior to discontinuation of antibiotic therapy, patients should be evaluated to ensure complete resolution of symptoms. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgical debridement</strong> − In addition to antibiotic treatment, surgical intervention is warranted in patients with driveline infection who have radiographic evidence of abscess, fluid collection, tissue gas, or progressive erythema and drainage despite appropriate antibiotic therapy. Surgical options include debridement of the driveline site, re-siting of the driveline, and drainage of abdominal wall abscesses  (<a class="graphic graphic_picture graphicRef141205" href="/d/graphic/141205.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent2">In patients who undergo surgery, operative cultures should be collected as described above. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who do not respond to antibiotics</strong> − For patients with persistent signs and symptoms of driveline infection despite antibiotic treatment, repeat imaging should be pursued to evaluate for interval change (including drainable fluid collection or abscess), and to assess for complications that may require surgical intervention. </p><p></p><p class="bulletIndent2">If imaging excludes a drainable collection, options for management of refractory infection include palliative antibiotic therapy, device replacement, device explant (if there is sufficient underlying cardiac function), or urgent cardiac transplantation (for eligible patients). A full cardiac assessment, surgical assessment, and multidisciplinary discussion is required to determine which strategy to pursue. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of suppressive antibiotic therapy</strong> − In general, we do not favor routine use of chronic suppressive antibiotic therapy for patients with driveline infection associated with a retained device who respond to therapy. Following cessation of antibiotic treatment, patients should be monitored closely for relapse of signs or symptoms consistent with infection. </p><p></p><p class="bulletIndent2">Use of suppressive antibiotic therapy may be reasonable in select patients who are awaiting heart transplantation, such as patients whose intraoperative cultures or histopathology demonstrate active infection. In addition, suppressive antibiotic therapy may be reasonable for patients with prior history of driveline infection who have completed antibiotic treatment for a repeat episode.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driveline infection with positive blood cultures</strong> – The approach to treatment of patients with driveline infection and positive blood cultures is as outlined for patients with endovascular (pump) infection. (See <a class="local">'Endovascular pump infection'</a> below.) </p><p></p><p class="headingAnchor" id="H1232736242"><span class="h2">Extravascular pump infection</span><span class="headingEndMark"> — </span>Extravascular pump infections are managed in the hospital and therapy consists of antibiotic therapy and surgical intervention [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic treatment</strong> – For patients with symptoms or signs of systemic infection, we initiate therapy with an empiric parenteral antibiotic regimen active against MRSA (such as <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>) and <em>Pseudomonas</em> spp (such as <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> or <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>); for patients with hemodynamic instability in the setting of underlying immunosuppression, some also include empiric antifungal treatment with an echinocandin. </p><p></p><p class="bulletIndent1">If there is coexisting discharge from a driveline or skin sinus, cultures should be obtained prior to initiation of antibiotics. If possible, antibiotic therapy should be deferred until tissue or fluid is obtained for culture (in the absence of driveline infection, this would be after a surgical debridement).</p><p></p><p class="bulletIndent1">Antibiotic therapy should be tailored to culture and susceptibility data when available. We treat patients with extravascular pump infection for at least six to eight weeks of parenteral antibiotic therapy, tailored to clinical improvement. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical management</strong> − Surgical intervention is required for definitive management of extravascular pump infection; in some circumstances, device replacement may be required  (<a class="graphic graphic_picture graphicRef141204" href="/d/graphic/141204.html" rel="external">picture 3</a>). Surgery consists of drainage and evacuation of fluid and debris around the pump, <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> washout, debridement of any inflamed tissue, and placement of drainage tubes. Antibiotic impregnated beads using absorbable calcium sulfate may be placed in the pocket. Surgery is undertaken through either an incision directly over the pump (typically a thoracotomy) or via a sternotomy (the latter carrying higher morbidity). Operative cultures should be collected as described above. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1">For patients with extensive abdominal or chest wall infection manifesting as discharging sinuses or extensive soft tissue destruction, device exchange is indicated. For patients whose device has eroded through the skin and is exposed, adjunctive surgical interventions may be required; these include use of a vacuum dressing and/or tissue flap coverage.</p><p></p><p class="bulletIndent1">For patients who are not surgical candidates for device exchange, serial debridement and washout of the pump pocket with antibiotic bead placement or cardiac transplantation are alternative approaches [<a href="#rid38">38</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suppressive antibiotic therapy</strong> − Following completion of parenteral therapy, we administer suppressive oral antibiotic therapy, even if the device is replaced, since the procedure involves an infected operative bed. We tailor decisions regarding the duration of antibiotic suppression to individual clinical circumstances including the reliability of source control, operative findings, and culture data. </p><p></p><p class="headingAnchor" id="H3345812567"><span class="h2">Endovascular pump infection</span><span class="headingEndMark"> — </span>Endovascular (pump) infection is managed in the hospital and consists of antibiotic therapy; in addition, patients should be evaluated for device replacement [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic treatment</strong> – We initiate empiric parenteral antibiotic treatment with a regimen active against MRSA (such as <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>) and <em>Pseudomonas </em>spp (such <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> or <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>); for patients with hemodynamic instability in the setting of underlying immunosuppression, some also include empiric antifungal treatment with an echinocandin. </p><p></p><p class="bulletIndent1">Antibiotic therapy should be tailored to culture and susceptibility data when available. We treat patients for at least six to eight weeks of parenteral antibiotic therapy, tailored to clinical improvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical management</strong> – Typically surgery is considered only for patients with persistent signs and symptoms of infection in the setting of parenteral antibiotic therapy. The optimal approach in such cases is uncertain. </p><p></p><p class="bulletIndent1">Options include palliative antibiotic therapy, device replacement, device explant (if there is sufficient underlying cardiac function), or urgent cardiac transplantation (for eligible patients). A full cardiac assessment, surgical assessment, and multidisciplinary discussion is required to determine which strategy to pursue. </p><p></p><p class="bulletIndent1">If surgery is pursued, operative cultures should be collected as described above. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suppressive antibiotic therapy</strong> − Following completion of parenteral therapy, we administer suppressive oral antibiotic therapy, even if the device is replaced, since the procedure involves an infected operative bed. We tailor decisions regarding the duration of antibiotic suppression to individual clinical circumstances including the reliability of source control, operative findings, and culture data. </p><p></p><p class="headingAnchor" id="H3171358453"><span class="h2">Patients who undergo transplantation</span><span class="headingEndMark"> — </span>The approach to antibiotic therapy after transplantation depends on the type of LVAD infection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driveline infection</strong> − For patients who undergo cardiac transplantation while receiving antibiotic treatment for driveline infection, the final duration of antibiotic treatment should be guided by operative findings, culture results, and histopathology. </p><p></p><p class="bulletIndent1">In the absence of evidence for infection, we continue antibiotics for one week after device removal; in the presence of evidence for infection, we continue antibiotics for two weeks after device removal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extravascular or endovascular pump infection</strong> − For patients who undergo cardiac transplantation while receiving antibiotic treatment for extravascular or endovascular pump infection, we continue antibiotics for two weeks after device removal and confirmation of sterilization of blood cultures. For patients who require further debridement or develop complications, a longer duration of antibiotic therapy may be warranted [<a href="#rid39">39</a>]. </p><p></p><p class="headingAnchor" id="H2890674193"><span class="h1">PREVENTION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial prophylaxis</strong> – Antimicrobial prophylaxis at the time of LVAD placement consists of an anti-staphylococcal agent (such as <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> or <a class="drug drug_general" data-topicid="9230" href="/d/drug information/9230.html" rel="external">cefuroxime</a>); for patients with methicillin-resistant<em> S. aureus</em> colonization, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> should be used  (<a class="graphic graphic_table graphicRef76499" href="/d/graphic/76499.html" rel="external">table 1</a>). We discontinue antimicrobial prophylaxis after 24 to 48 hours, irrespective of whether drains remain in place [<a href="#rid4">4,40</a>]. There is no role for additional gram-negative or fungal prophylaxis unless guided by institutional epidemiology data [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1">Prospective trials are needed to further define the optimal approach to prophylaxis. In a retrospective review including 239 patients who underwent LVAD implantation, 199 patients received a single-drug prophylaxis regimen (<a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a>) and 40 received a multidrug prophylaxis regimen (vancomycin, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, and <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, with or without <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>); the rate of LVAD infection at 90 days was comparable between the groups (3 versus 2 patients), and there was no difference in all-cause mortality at one year [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical technique</strong> – Strict aseptic surgical and anesthetic technique is necessary to prevent introduction of bacteria at time of LVAD surgery. Pump preparation and handling must be performed in a strictly sterile manner.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driveline site care</strong> – The driveline should be immobilized using a binder or anchoring device; fixation of the driveline to the skin for two to three weeks after implantation may facilitate healing and decrease potential for trauma or irritation. The driveline should be covered with a sterile dressing at all times. The dressing should be changed one to three times a week; patients should be instructed to do this with aseptic technique [<a href="#rid42">42</a>]. Showering prior to healing of the driveline site (eg, during the first month after implantation) should be minimized as this may increase risk for infection.</p><p></p><p class="headingAnchor" id="H3195558770"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Morbidity and mortality varies by the type of LVAD infection. In one study including more than 10,000 LVAD recipients, one-year survival rates after initial diagnosis of driveline infection, extravascular pump infection, and endovascular pump infection were 87, 58, and 66 percent, respectively [<a href="#rid5">5</a>]. In another study including more than 12,000 patients, ventricular assist device (VAD)-specific infection was associated with death hazard of 2.92 (95% CI 2.57-3.32) [<a href="#rid43">43</a>].</p><p>In an international multicenter study including 10,171 patients with VAD (after first VAD-specific infection), 12-month survival was lower among patients with endovascular or extravascular pump infection (58 and 66 percent, respectively) than among patients with driveline infection (86 percent) [<a href="#rid5">5</a>].</p><p>Compared with patients with LVADs who do not undergo transplantation due to infection, patients who undergo transplantation due to infection have similar outcomes [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H3959429103"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – A left ventricular assist device (LVAD) can be used to treat advanced heart failure, as a bridge to heart transplantation in eligible patients, or as destination therapy for patients who are not eligible for transplant. LVAD components are shown in the figure  (<a class="graphic graphic_figure graphicRef138618" href="/d/graphic/138618.html" rel="external">figure 1</a>). Types of LVAD infection include driveline infection, extravascular pump infection, and endovascular pump infection; driveline infection is the most common. (See <a class="local">'Types of LVAD infection'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – The microbiology of LVAD infections consist largely of gram-positive organisms (<em>Staphylococcus aureus</em>, coagulase-negative staphylococci) and Gram-negative pathogens (including <em>Pseudomonas</em> spp); less common organisms include fungi and nontuberculous mycobacteria. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Most patients with LVAD infection present with erythema and/or purulent discharge at the driveline exit site, pain along the driveline tract, or pain involving the left chest wall (the typical LVAD pump site)  (<a class="graphic graphic_picture graphicRef141203" href="/d/graphic/141203.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef141205" href="/d/graphic/141205.html" rel="external">picture 2</a>). Other manifestations may include fever or other systemic symptoms, heart failure exacerbation, or other cardiac abnormalities such as arrhythmia. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The initial evaluation includes blood cultures, drainage cultures (if drainage is present at the driveline exit site), and additional studies guided by symptoms. For patients with inflammation at the driveline and/or pocket sites, we obtain computed tomography of the chest and abdomen to evaluate for drainable collection and assess for complications that may require surgical intervention. For patients with systemic symptoms (such as hemodynamic instability, bacteremia, device malfunction, and/or vascular or immunologic phenomena), we obtain echocardiography. For patients who undergo surgery, operative material should be submitted for bacterial, mycobacterial, and fungal stain and culture, as well as histopathology. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Driveline infection</strong> – A definitive diagnosis is based on drainage culture obtained from the driveline exit site  (<a class="graphic graphic_picture graphicRef141203" href="/d/graphic/141203.html" rel="external">picture 1</a>). A presumptive clinical diagnosis may be made in the setting of signs of infection at the driveline site. Uncomplicated infection is limited to inflammation and drainage at the driveline exit site or surrounding tissues; complicated infection includes these findings as well as abscess, necrosis, or sepsis. (See <a class="local">'Driveline infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extravascular pump infection</strong> – A definitive diagnosis is based on positive operative cultures or histopathologic findings. For patients who do not undergo surgery, a presumptive clinical diagnosis may be made in the setting of radiographic imaging demonstrating findings consistent with an infection (including fluid collection, enhancement, gas, or sinus tract) and positive culture of image-guided aspiration material  (<a class="graphic graphic_picture graphicRef141204" href="/d/graphic/141204.html" rel="external">picture 3</a>). (See <a class="local">'Extravascular pump infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endovascular pump infection</strong> – The diagnosis may be established clinically by positive blood cultures as well as echocardiographic and/or radiographic findings (including echodensity, intracardiac mass, mass around the inflow cannula, or abscess). If the device is removed, additional diagnostic criteria include positive operative cultures and histopathologic criteria. Evaluation for alternative causes of bacteremia should also be pursued. (See <a class="local">'Endovascular pump infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Driveline infection</strong> (see <a class="local">'Driveline infection'</a> above): </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Uncomplicated</strong> – For patients who are clinically stable but have substantial erythema, drainage, or skin warmth, we suggest initiation of empiric oral antibiotic therapy with a regimen active against methicillin-resistant<em> S. aureus</em> (MRSA) and <em>Pseudomonas</em> spp (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Antibiotic therapy should be tailored to culture results and susceptibility data when available. We continue treatment for at least two to four weeks, after which the duration should be guided by clinical improvement. Prior to discontinuation of antibiotic therapy, patients should be evaluated to ensure complete resolution of symptoms. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Complicated</strong> – For patients with hemodynamic instability and/or progressive inflammation at the driveline site, we suggest initiation of empiric parenteral antibiotic therapy with a regimen active against MRSA and <em>Pseudomonas</em> spp (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); for those with underlying immunosuppression, some also include empiric antifungal treatment with an echinocandin.</p><p></p><p class="bulletIndent3">For patients with persistent signs and symptoms of driveline infection despite antibiotic treatment, we pursue repeat imaging to evaluate for interval change and to assess for complications. </p><p></p><p class="bulletIndent3">Surgical intervention is warranted in patients with radiographic evidence of abscess, fluid collection, tissue gas, or progressive erythema and drainage despite appropriate antibiotic therapy  (<a class="graphic graphic_picture graphicRef141205" href="/d/graphic/141205.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent3">Completion of antibiotic therapy with parenteral therapy is preferred; if drainage culture susceptibility data permit, highly bioavailable oral agents may be considered. We continue treatment until clinical stabilization is observed (usually six to eight weeks). </p><p></p><p class="bulletIndent3">In general, we do not favor routine use of chronic suppressive antibiotic therapy for patients with driveline infection and retained device who respond to initial therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extravascular pump infection</strong> – Management of extravascular pump infection consists of antibiotic therapy and surgical intervention. The approach to empiric antibiotic therapy is as described above for complicated driveline infection. We continue parenteral antibiotic therapy for at least six to eight weeks, tailored to clinical improvement. Thereafter, we administer suppressive oral antibiotic therapy, even if the device is replaced, since the procedure involves an infected operative bed. (See <a class="local">'Extravascular pump infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endovascular pump infection</strong> – Management of endovascular pump infection consists of antibiotic therapy; in addition, patients should be evaluated for device replacement. (See <a class="local">'Endovascular pump infection'</a> above.)</p><p></p><p class="bulletIndent2">The approach to empiric therapy is as described above for complicated driveline infection. (See <a class="local">'Driveline infection'</a> above.)</p><p></p><p class="bulletIndent2">Typically, we consider surgery only for patients with persistent signs and symptoms of infection in the setting of parenteral antibiotic therapy. The optimal approach in such cases is uncertain; options include palliative antibiotic therapy, device replacement, device explant (if there is sufficient underlying cardiac function), or urgent cardiac transplantation (for eligible patients). A full cardiac assessment, surgical assessment, and multidisciplinary discussion is required to determine which strategy to pursue. </p><p></p><p class="bulletIndent2">We continue treatment for at least six to eight weeks of parenteral antibiotic therapy, tailored to clinical improvement. Thereafter, we administer suppressive oral antibiotic therapy, even if the device is replaced, since the procedure involves an infected operative bed. </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miller L, Birks E, Guglin M, et al. Use of Ventricular Assist Devices and Heart Transplantation for Advanced Heart Failure. Circ Res 2019; 124:1658.</a></li><li><a class="nounderline abstract_t">Zinoviev R, Lippincott CK, Keller SC, Gilotra NA. In Full Flow: Left Ventricular Assist Device Infections in the Modern Era. Open Forum Infect Dis 2020; 7:ofaa124.</a></li><li><a class="nounderline abstract_t">Hannan MM, Husain S, Mattner F, et al. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant 2011; 30:375.</a></li><li><a class="nounderline abstract_t">Kusne S, Mooney M, Danziger-Isakov L, et al. An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. J Heart Lung Transplant 2017; 36:1137.</a></li><li><a class="nounderline abstract_t">Hannan MM, Xie R, Cowger J, et al. Epidemiology of infection in mechanical circulatory support: A global analysis from the ISHLT Mechanically Assisted Circulatory Support Registry. J Heart Lung Transplant 2019; 38:364.</a></li><li><a class="nounderline abstract_t">Molina EJ, Shah P, Kiernan MS, et al. The Society of Thoracic Surgeons Intermacs 2020 Annual Report. Ann Thorac Surg 2021; 111:778.</a></li><li><a class="nounderline abstract_t">Pienta M, Shore S, Pagani FD, et al. Rates and types of infections in left ventricular assist device recipients: A scoping review. JTCVS Open 2021; 8:405.</a></li><li><a class="nounderline abstract_t">Goldstein DJ, Naftel D, Holman W, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant 2012; 31:1151.</a></li><li><a class="nounderline abstract_t">Zahr F, Genovese E, Mathier M, et al. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg 2011; 92:1420.</a></li><li><a class="nounderline abstract_t">Asleh R, Briasoulis A, Schettle SD, et al. Impact of Diabetes Mellitus on Outcomes in Patients Supported With Left Ventricular Assist Devices: A Single Institutional 9-Year Experience. Circ Heart Fail 2017; 10.</a></li><li><a class="nounderline abstract_t">Patel CB, Blue L, Cagliostro B, et al. Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial. J Heart Lung Transplant 2020; 39:774.</a></li><li><a class="nounderline abstract_t">Khan MS, Yuzefpolskaya M, Memon MM, et al. Outcomes Associated with Obesity in Patients Undergoing Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis. ASAIO J 2020; 66:401.</a></li><li><a class="nounderline abstract_t">DeFilippis EM, Breathett K, Donald EM, et al. Psychosocial Risk and Its Association With Outcomes in Continuous-Flow Left Ventricular Assist Device Patients. Circ Heart Fail 2020; 13:e006910.</a></li><li><a class="nounderline abstract_t">Papathanasiou M, Tsourelis L, Pizanis N, et al. Resternotomy does not adversely affect outcome after left ventricular assist device implantation. Eur J Med Res 2017; 22:46.</a></li><li><a class="nounderline abstract_t">Tattevin P, Flécher E, Auffret V, et al. Risk factors and prognostic impact of left ventricular assist device-associated infections. Am Heart J 2019; 214:69.</a></li><li><a class="nounderline abstract_t">Dean D, Kallel F, Ewald GA, et al. Reduction in driveline infection rates: Results from the HeartMate II Multicenter Driveline Silicone Skin Interface (SSI) Registry. J Heart Lung Transplant 2015; 34:781.</a></li><li><a class="nounderline abstract_t">Toba FA, Akashi H, Arrecubieta C, Lowy FD. Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections. J Thorac Cardiovasc Surg 2011; 141:1259.</a></li><li><a class="nounderline abstract_t">Qu Y, McGiffin D, Hayward C, et al. Characterization of infected, explanted ventricular assist device drivelines: The role of biofilms and microgaps in the driveline tunnel. J Heart Lung Transplant 2020; 39:1289.</a></li><li><a class="nounderline abstract_t">Qu Y, McGiffin D, Kure C, et al. Biofilm formation and migration on ventricular assist device drivelines. J Thorac Cardiovasc Surg 2020; 159:491.</a></li><li><a class="nounderline abstract_t">Blanco-Guzman MO, Wang X, Vader JM, et al. Epidemiology of Left Ventricular Assist Device Infections: Findings From a Large Nonregistry Cohort. Clin Infect Dis 2021; 72:190.</a></li><li><a class="nounderline abstract_t">Nienaber JJ, Kusne S, Riaz T, et al. Clinical manifestations and management of left ventricular assist device-associated infections. Clin Infect Dis 2013; 57:1438.</a></li><li class="breakAll">Surgical Site Infection Event (SSI). National Healthcare Safety Network. Available at: https://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf (Accessed on September 06, 2022).</li><li><a class="nounderline abstract_t">Lehnert AL, Hart A, Brouse SD, et al. Left ventricular assist device-related infections: does the time of onset matter? J Artif Organs 2019; 22:98.</a></li><li><a class="nounderline abstract_t">Aburjania N, Sherazi S, Tchantchaleishvili V, et al. Stopping conventional showering decreases Pseudomonas infections in left ventricular assist device patients. Int J Artif Organs 2017; 40:282.</a></li><li><a class="nounderline abstract_t">Donahey EE, Polly DM, Vega JD, et al. Multidrug-Resistant Organism Infections in Patients with Left Ventricular Assist Devices. Tex Heart Inst J 2015; 42:522.</a></li><li><a class="nounderline abstract_t">Aslam S, Hernandez M, Thornby J, et al. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect Dis 2010; 50:664.</a></li><li><a class="nounderline abstract_t">Tan SYL, Chung SJ, Tan TE, et al. An unusual case of Scedosporium apiospermum fungaemia in an immunocompetent patient with a left ventricular assist device and an implantable cardiac device. Access Microbiol 2020; 2:acmi000148.</a></li><li><a class="nounderline abstract_t">Barbone A, Pini D, Grossi P, et al. Aspergillus left ventricular assist device endocarditis. Ital Heart J 2004; 5:876.</a></li><li><a class="nounderline abstract_t">Cunningham HE, Tessmann PB, Lachiewicz AM. Aspergillus flavus Left Ventricular Assist Device Driveline Exit Site Infection. Infect Dis Clin Prac 2020; 28:99.</a></li><li><a class="nounderline abstract_t">Radcliffe C, Doilicho N, Grant M. Nontuberculous mycobacterial infections in left ventricular assist device patients. J Card Surg 2020; 35:1138.</a></li><li><a class="nounderline abstract_t">Siméon S, Flécher E, Revest M, et al. Left ventricular assist device-related infections: a multicentric study. Clin Microbiol Infect 2017; 23:748.</a></li><li><a class="nounderline abstract_t">Saritas T, Brandenburg V, Federico G, et al. Glomerulonephritis triggered by a chronically infected left ventricular assist device. Lancet 2015; 386:2363.</a></li><li><a class="nounderline abstract_t">Carr CM, Jacob J, Park SJ, et al. CT of left ventricular assist devices. Radiographics 2010; 30:429.</a></li><li><a class="nounderline abstract_t">Ten Hove D, Treglia G, Slart RHJA, et al. The value of 18F-FDG PET/CT for the diagnosis of device-related infections in patients with a left ventricular assist device: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021; 48:241.</a></li><li><a class="nounderline abstract_t">Shroff GS, Ocazionez D, Akkanti B, et al. CT Imaging of Complications Associated with Continuous-Flow Left Ventricular Assist Devices (LVADs). Semin Ultrasound CT MR 2017; 38:616.</a></li><li><a class="nounderline abstract_t">Martin BJ, Luc JGY, Maruyama M, et al. Driveline Site Is Not a Predictor of Infection After Ventricular Assist Device Implantation. ASAIO J 2018; 64:616.</a></li><li><a class="nounderline abstract_t">Aburjania N, Hay CM, Sohail MR. Continuous-flow left ventricular assist device systems infections: current outcomes and management strategies. Ann Cardiothorac Surg 2021; 10:233.</a></li><li><a class="nounderline abstract_t">Kretlow J, Izaddoost SA, Ho J, Frazier OH. Use of Antibiotic Beads in the Treatment of Left Ventricular Assist Device Infections. Journal of Heart and Lung Transplantation 2013; 32:S276.</a></li><li><a class="nounderline abstract_t">Esquer Garrigos Z, Castillo Almeida NE, Gurram P, et al. Management and Outcome of Left Ventricular Assist Device Infections in Patients Undergoing Cardiac Transplantation. Open Forum Infect Dis 2020; 7:ofaa303.</a></li><li><a class="nounderline abstract_t">Mertz D, Johnstone J, Loeb M. Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta-analysis. Ann Surg 2011; 254:48.</a></li><li><a class="nounderline abstract_t">Aburjania N, Ertmer BM, Farid S, et al. Single Versus Multidrug Regimen for Surgical Infection Prophylaxis in Left Ventricular Assist Device Implantation. ASAIO J 2018; 64:735.</a></li><li><a class="nounderline abstract_t">Koken ZO, Yalcin YC, van Netten D, et al. Driveline exit-site care protocols in patients with left ventricular assist devices: a systematic review. Eur J Cardiothorac Surg 2021; 60:506.</a></li><li><a class="nounderline abstract_t">Zhou S, Yang G, Zhang M, et al. Mortality following durable left ventricular assist device implantation by timing and type of first infection. J Thorac Cardiovasc Surg 2023; 166:570.</a></li><li><a class="nounderline abstract_t">Parikh A, Halista M, Raymond S, et al. Relation of Left Ventricular Assist Device Infections With Cardiac Transplant Outcomes. Am J Cardiol 2021; 160:67.</a></li></ol></div><div id="topicVersionRevision">Topic 132040 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31120817" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Use of Ventricular Assist Devices and Heart Transplantation for Advanced Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32405511" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : In Full Flow: Left Ventricular Assist Device Infections in the Modern Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21419995" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Working formulation for the standardization of definitions of infections in patients using ventricular assist devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28781010" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30733158" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiology of infection in mechanical circulatory support: A global analysis from the ISHLT Mechanically Assisted Circulatory Support Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33465365" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Society of Thoracic Surgeons Intermacs 2020 Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36004147" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Rates and types of infections in left ventricular assist device recipients: A scoping review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22766022" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Continuous-flow devices and percutaneous site infections: clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21958791" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141856" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impact of Diabetes Mellitus on Outcomes in Patients Supported With Left Ventricular Assist Devices: A Single Institutional 9-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32276809" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31192852" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcomes Associated with Obesity in Patients Undergoing Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32894983" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Psychosocial Risk and Its Association With Outcomes in Continuous-Flow Left Ventricular Assist Device Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141690" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Resternotomy does not adversely affect outcome after left ventricular assist device implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31174053" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk factors and prognostic impact of left ventricular assist device-associated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25735901" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reduction in driveline infection rates: Results from the HeartMate II Multicenter Driveline Silicone Skin Interface (SSI) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709333" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32771438" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Characterization of infected, explanted ventricular assist device drivelines: The role of biofilms and microgaps in the driveline tunnel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30955967" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Biofilm formation and migration on ventricular assist device drivelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31925953" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Epidemiology of Left Ventricular Assist Device Infections: Findings From a Large Nonregistry Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943820" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical manifestations and management of left ventricular assist device-associated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943820" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical manifestations and management of left ventricular assist device-associated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30386926" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Left ventricular assist device-related infections: does the time of onset matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28430297" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Stopping conventional showering decreases Pseudomonas infections in left ventricular assist device patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26664303" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Multidrug-Resistant Organism Infections in Patients with Left Ventricular Assist Devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20113174" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factors and outcomes of fungal ventricular-assist device infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33195980" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An unusual case of Scedosporium apiospermum fungaemia in an immunocompetent patient with a left ventricular assist device and an implantable cardiac device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15633446" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Aspergillus left ventricular assist device endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Aspergillus flavus Left Ventricular Assist Device Driveline Exit Site Infection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32253770" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nontuberculous mycobacterial infections in left ventricular assist device patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323195" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Left ventricular assist device-related infections: a multicentric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26681291" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Glomerulonephritis triggered by a chronically infected left ventricular assist device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20228327" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : CT of left ventricular assist devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32594196" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The value of 18F-FDG PET/CT for the diagnosis of device-related infections in patients with a left ventricular assist device: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29179901" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : CT Imaging of Complications Associated with Continuous-Flow Left Ventricular Assist Devices (LVADs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29035899" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Driveline Site Is Not a Predictor of Infection After Ventricular Assist Device Implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33842217" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Continuous-flow left ventricular assist device systems infections: current outcomes and management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Use of Antibiotic Beads in the Treatment of Left Ventricular Assist Device Infections</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32818144" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Management and Outcome of Left Ventricular Assist Device Infections in Patients Undergoing Cardiac Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412147" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29095735" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Single Versus Multidrug Regimen for Surgical Infection Prophylaxis in Left Ventricular Assist Device Implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33963835" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Driveline exit-site care protocols in patients with left ventricular assist devices: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34895722" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mortality following durable left ventricular assist device implantation by timing and type of first infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34615608" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Relation of Left Ventricular Assist Device Infections With Cardiac Transplant Outcomes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
